NCT00388037 - Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity CancerStage IIIA Fallopian Tube CancerStage IIIA Ovarian Epithelial CancerStage IIIA Primary Peritoneal Cavity CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian Epithelial CancerStage IIIB Primary Peritoneal Cavity CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian Epithelial CancerStage IIIC Primary Peritoneal Cavity CancerStage IV Fallopian Tube CancerStage IV Ovarian Epithelial CancerStage IV Primary Peritoneal Cavity Cancer

Interventions

DRUG

sunitinib malate

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

K7L 3N6

National Cancer Institute of Canada Clinical Trials Group, Kingston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH